Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Chief Financial Officer | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
X4 Pharmaceuticals, Inc
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 155,983 |
Reported balance
After 2026-10-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-01 · Sale · Disposed 11,767 · Balance 155,983 F1: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $2.82 to $2.92, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Of the shares of common stock reported, 64,418 shares represent restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $2.82 to $2.92, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Of the shares of common stock reported, 64,418 shares represent restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CTI BIOPHARMA CORP
Report date June 26, 2023 · Filed June 26, 2023
Section 16 reporting ended · disclosed 2023-06-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 1
1 source rowRow 1 · 2023-06-26 · Other · Disposed 17,547 · Balance 0 F1: Includes 420 shares of common stock of the Issuer ("Company Common Stock") purchased by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan prior to the date of this Form 4. F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of Company Common Stock and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $9.10 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.25 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-26 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.19 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-26 · Disposition to issuer · Disposed 315,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-06-26 · Disposition to issuer · Disposed 83,396 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-06-26 · Disposition to issuer · Disposed 270,216 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-06-26 · Disposition to issuer · Disposed 340,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-06-26 · Disposition to issuer · Disposed 150,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.49 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-06-26 · Disposition to issuer · Disposed 280,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.55 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-06-26 · Disposition to issuer · Disposed 200,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 420 shares of common stock of the Issuer ("Company Common Stock") purchased by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan prior to the date of this Form 4.
F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of Company Common Stock and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $9.10 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2022 Filed Oct 3, 2022 18:26 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 100 | $6.01 | $601.00 |
DisclosureSEC source: 0000891293-22-000046 · primary_doc.xml · nonDerivative · entry 4 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,913 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 18:26 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 100 | $0.95 | $94.89 |
DisclosureSEC source: 0000891293-22-000046 · primary_doc.xml · nonDerivative · entry 3 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 18:26 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 800 | $6.00 | $4,800.00 |
DisclosureSEC source: 0000891293-22-000046 · primary_doc.xml · nonDerivative · entry 2 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,913 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 18:26 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 800 | $0.95 | $759.12 |
DisclosureSEC source: 0000891293-22-000046 · primary_doc.xml · nonDerivative · entry 1 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 16:59 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 22,592 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000891293-22-000045 · primary_doc.xml · derivative · entry 4 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,408 Underlying: Common Stock · 22,592 shares Expires 2029-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 16:59 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 22,592 | $6.02 | $136,003.84 |
DisclosureSEC source: 0000891293-22-000045 · primary_doc.xml · nonDerivative · entry 3 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,913 F2 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 16:59 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 22,592 | $0.95 | $21,437.55 |
DisclosureSEC source: 0000891293-22-000045 · primary_doc.xml · nonDerivative · entry 2 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,505 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2022 Filed Sep 20, 2022 16:59 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Grantcommon stock | 9,516 | $2.12 | $20,140.61 |
DisclosureSEC source: 0000891293-22-000045 · primary_doc.xml · nonDerivative · entry 1 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,913 F1 · kind: Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan. Read SEC document |
| June 17, 2022 Filed Jun 17, 2022 16:57 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0000891293-22-000033 · primary_doc.xml · derivative · entry 6 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 50,000 shares Expires 2031-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One sixth of the shares underlying the option vested on 9/10/2021 and semi-annually thereafter until all the underlying shares will be fully vested on 3/10/2024. Read SEC document |
| June 17, 2022 Filed Jun 17, 2022 16:57 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0000891293-22-000033 · primary_doc.xml · derivative · entry 5 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,000 Underlying: Common Stock · 10,000 shares Expires 2030-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One sixth of the shares underlying the option vested on 9/11/2020 and semi-annually thereafter until all the underlying shares will be fully vested on 3/11/2023. Read SEC document |
| June 17, 2022 Filed Jun 17, 2022 16:57 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 50,000 | $6.25 | $312,505.00 |
DisclosureSEC source: 0000891293-22-000033 · primary_doc.xml · nonDerivative · entry 4 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,397 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| June 17, 2022 Filed Jun 17, 2022 16:57 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 50,000 | $3.30 | $165,000.00 |
DisclosureSEC source: 0000891293-22-000033 · primary_doc.xml · nonDerivative · entry 3 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2022 Filed Jun 17, 2022 16:57 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 10,000 | $6.00 | $60,000.00 |
DisclosureSEC source: 0000891293-22-000033 · primary_doc.xml · nonDerivative · entry 2 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,397 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| June 17, 2022 Filed Jun 17, 2022 16:57 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 10,000 | $1.00 | $10,000.00 |
DisclosureSEC source: 0000891293-22-000033 · primary_doc.xml · nonDerivative · entry 1 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 16:19 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000891293-22-000032 · primary_doc.xml · derivative · entry 3 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 490,000 Underlying: Common Stock · 10,000 shares Expires 2029-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 16:19 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 10,000 | $5.50 | $55,000.00 |
DisclosureSEC source: 0000891293-22-000032 · primary_doc.xml · nonDerivative · entry 2 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,397 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 16:19 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 10,000 | $0.95 | $9,489.00 |
DisclosureSEC source: 0000891293-22-000032 · primary_doc.xml · nonDerivative · entry 1 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 19:41 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantStock Option (right to buy) · Derivative | 280,000 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0000899243-22-010771 · doc4.xml · derivative · entry 3 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2032-03-09 F2 · derivative.exercise_date: The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates. Read SEC document |
| December 31, 2021 Filed Mar 11, 2022 19:41 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantCommon Stock | 1,817 | $2.11 | $3,830.24 |
DisclosureSEC source: 0000899243-22-010771 · doc4.xml · nonDerivative · entry 2 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,397 F1 · kind: Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan. Read SEC document |
| June 30, 2021 Filed Mar 11, 2022 19:41 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantCommon Stock | 1,782 | $2.13 | $3,786.75 |
DisclosureSEC source: 0000899243-22-010771 · doc4.xml · nonDerivative · entry 1 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,580 F1 · kind: Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 18:41 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | SaleStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0000899243-21-011363 · doc4.xml · derivative · entry 2 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-03-10 F2 · derivative.exercise_date: The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates. The stock option is also subject to stockholder approval of an increase in the share reserve under the Company's 2017 Equity Incentive Plan, which approval must occur within one year from the grant date. Read SEC document |
| July 01, 2020 Filed Mar 12, 2021 18:41 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantCommon Stock | 3,798 | $0.98 | $3,722.04 |
DisclosureSEC source: 0000899243-21-011363 · doc4.xml · nonDerivative · entry 1 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,798 F1 · kind: Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 19:51 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantNon-qualified Stock Option · Derivative | 350,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0000891293-20-000018 · primary_doc.xml · derivative · entry 1 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common stock · 350,000 shares Expires 2030-03-11 F1 · derivative.exercise_date: The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates. The stock option is also subject to stockholder approval of an increase in the share reserve under the 2017 Equity Incentive Plan of the Company, which approval must occur within one year from the grant date. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 18:46 UTC | CTI BIOPHARMA CORP ctic · Entity 111865 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000891293-19-000010 · primary_doc.xml · derivative · entry 1 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2029-02-19 F1 · derivative.exercise_date: 1/3 of the shares subject to the Option shall vest on the one year anniversary of February 19, 2019, and 1/3 of the shares shall vest annually thereafter on February 19, subject to Reporting Person continuing to be an employee or service provider on each date, such that the Option shall be fully vested on February 19, 2022. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 17:03 UTC | CTI BIOPHARMA CORP ctic · Entity 111865 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000891293-18-000087 · primary_doc.xml · derivative · entry 1 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2028-09-18 F1 · derivative.exercise_date: The stock options will fully vest upon the Compensation Committee's certification of the European Medicines Agency approval of the Marketing Authorization Application for Pacritinib, assuming that such approval occurs no later than September 30, 2019. Read SEC document |
| May 16, 2018 Filed May 17, 2018 16:49 UTC | CTI BIOPHARMA CORP ctic · Entity 111865 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 83,396 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0000891293-18-000058 · primary_doc.xml · derivative · entry 1 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,396 Underlying: Common Stock · 83,396 shares Expires 2028-05-16 F1 · derivative.exercise_date: The stock option will vest in six equal semi-annual installments over a three-year period commencing on March 9, 2018 subject to continued employment with the Company through the applicable vesting dates, such that the option will be fully vested on March 9, 2021. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 16:12 UTC | CTI BIOPHARMA CORP ctic · Entity 111865 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 315,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0000891293-17-000106 · primary_doc.xml · derivative · entry 1 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,000 Underlying: Common Stock · 315,000 shares Expires 2027-09-29 F1 · derivative.exercise_date: The stock options will vest in six equal semi-annual installments over a three-year period beginning September 29, 2017 subject to continued employment by CTIC through the applicable vesting dates. Read SEC document |
| August 31, 2017 Filed Oct 19, 2017 16:11 UTC Amendment | CTI BIOPHARMA CORP ctic · Entity 111865 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0000891293-17-000109 · primary_doc.xml · derivative · entry 1 KIRSKE DAVID · CIK 0001276750 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-08-31 F1 · security: On August 3, 2017, the reporting person filed a Form 4 which inadvertently reported that, on August 1, 2017 (the first day of the reporting person's employment with CTIC), CTIC granted the reporting person an option to purchase 25,000 shares of CTIC Common Stock. In fact, as reported in this amendment, such stock option was not granted until August 31, 2017 (the last day of the month in which the reporting person was first employed by CTIC). F2 · derivative.exercise_date: The stock options will vest over a period of one year from the grant date in twelve equal monthly installments. The grant will accelerate and fully vest should Mr. Kirske's employment be terminated by the Company without cause within the first six months after the grant date. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 19:02 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0000899243-17-019737 · doc4.xml · derivative · entry 1 KIRSKE DAVID · CIK 0001276750 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-08-01 F1 · derivative.exercise_date: The stock options will vest over a period of one year from the grant date in twelve equal monthly installments. The grant will accelerate and fully vest should Mr. Kirske's employment be terminated by the Company without cause within the first six months after the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.